NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
97
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,732.77 | 30.82 | 0.40% |
| DAX 40 | 22,359.27 | 58.52 | 0.26% |
| Dow JONES (US) | 45,298.08 | 131.44 | 0.29% |
| FTSE 100 | 10,073.06 | 105.71 | 1.06% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,923.88 | 24.47 | -0.12% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,373.28 | 4.43 | 0.07% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |